187 related articles for article (PubMed ID: 23816163)
1. How lenalidomide is changing the treatment of patients with multiple myeloma.
Dimopoulos MA; Terpos E; Niesvizky R
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frølund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist UH; Nahi H
Cancer Med; 2018 Jun; 7(6):2256-2268. PubMed ID: 29673108
[TBL] [Abstract][Full Text] [Related]
3. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Zonder JA; Crowley J; Hussein MA; Bolejack V; Moore DF; Whittenberger BF; Abidi MH; Durie BG; Barlogie B
Blood; 2010 Dec; 116(26):5838-41. PubMed ID: 20876454
[TBL] [Abstract][Full Text] [Related]
5. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
[TBL] [Abstract][Full Text] [Related]
6. Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.
Reece D; Kouroukis CT; Leblanc R; Sebag M; Song K; Ashkenas J
Adv Hematol; 2012; 2012():621958. PubMed ID: 23097669
[TBL] [Abstract][Full Text] [Related]
7. Development of target-specific treatments in multiple myeloma.
Chanan-Khan AA; Borrello I; Lee KP; Reece DE
Br J Haematol; 2010 Oct; 151(1):3-15. PubMed ID: 20618339
[TBL] [Abstract][Full Text] [Related]
8. Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial.
White DJ; Paul N; Macdonald DA; Meyer RM; Shepherd LE
Curr Oncol; 2007 Apr; 14(2):61-5. PubMed ID: 17576467
[TBL] [Abstract][Full Text] [Related]
9. Aponermin: First Approval.
Dhillon S
Drugs; 2024 Apr; 84(4):459-466. PubMed ID: 38441805
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide-induced eosinophilic pneumonia.
Toma A; Rapoport AP; Burke A; Sachdeva A
Respirol Case Rep; 2017 Jul; 5(4):e00233. PubMed ID: 28451433
[TBL] [Abstract][Full Text] [Related]
11. A single-centre retrospective review of treatment responses and adverse events of thalidomide in patients with inflammatory skin disease.
McSweeney SM; Mounsey S; Arujuna N; Garibaldinos T; Sarkany R; Fassihi H
Clin Exp Dermatol; 2024 Jan; 49(2):168-170. PubMed ID: 37652049
[No Abstract] [Full Text] [Related]
12. Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma.
Raedler LA
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):140-3. PubMed ID: 27668061
[No Abstract] [Full Text] [Related]
13. Efficacy of Immunomodulatory Drugs in Combination With Dexamethasone in Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits.
Zhou H; Li M; Zeng C; Chen Z; Zhang T; Cheng Z
Kidney Int Rep; 2022 Oct; 7(10):2166-2175. PubMed ID: 36217516
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
[TBL] [Abstract][Full Text] [Related]
15. Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.
Sharkey MM; McKavanagh D; Walpole E; Mollee P; Hollingworth SA
Int J Clin Pharm; 2017 Aug; 39(4):836-843. PubMed ID: 28573439
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.
Wang J; Guo H; Zhou X
Onco Targets Ther; 2015; 8():1277-84. PubMed ID: 26082645
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.
Weiss D; Knight R; Zhou S; Palmisano M; Chen N
Clin Drug Investig; 2015 Jul; 35(7):455-61. PubMed ID: 26024727
[TBL] [Abstract][Full Text] [Related]
19. Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea.
Kim HJ; Yoon SS; Eom HS; Kim K; Kim JS; Lee JJ; Bang SM; Min CK; Park JS; Lee JH;
Blood Res; 2015 Mar; 50(1):7-18. PubMed ID: 25830125
[TBL] [Abstract][Full Text] [Related]
20. No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.
Chen N; Weiss D; Reyes J; Liu L; Kasserra C; Wang X; Zhou S; Kumar G; Weiss L; Palmisano M
Cancer Chemother Pharmacol; 2014 May; 73(5):1031-9. PubMed ID: 24659021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
